Publicaciones en las que colabora con María Esther Larrea Leoz (29)

2022

  1. Effect of topical berberine in murine cutaneous leishmaniasis lesions

    Journal of Antimicrobial Chemotherapy, Vol. 77, Núm. 4, pp. 1072-1081

  2. Repurposing the Antibacterial Agents Peptide 19-4LF and Peptide 19-2.5 for Treatment of Cutaneous Leishmaniasis

    Pharmaceutics, Vol. 14, Núm. 11

2021

  1. Changes in the nanoparticle uptake and distribution caused by an intramacrophagic parasitic infection

    Nanoscale, Vol. 13, Núm. 41, pp. 17486-17503

2020

  1. Berberine-loaded liposomes for the treatment of leishmania infantum-infected balb/c mice

    Pharmaceutics, Vol. 12, Núm. 9, pp. 1-18

2019

  1. Leishmanicidal activity of isoselenocyanate derivatives

    Antimicrobial Agents and Chemotherapy, Vol. 63, Núm. 2

2018

  1. Combination of paromomycin plus human anti-TNF-α antibodies to control the local inflammatory response in BALB/ mice with cutaneous leishmaniasis lesions

    Journal of Dermatological Science, Vol. 92, Núm. 1, pp. 78-88

2017

  1. Skin vaccination using microneedles coated with a plasmid DNA cocktail encoding nucleosomal histones of Leishmania spp.

    International Journal of Pharmaceutics, Vol. 533, Núm. 1, pp. 236-244

2016

  1. Gene expression analysis during acute hepatitis C virus infection associates dendritic cell activation with viral clearance

    Journal of Medical Virology, Vol. 88, Núm. 5, pp. 843-851

2015

  1. Assessment of β-lapachone loaded in lecithin-chitosan nanoparticles for the topical treatment of cutaneous leishmaniasis in L. major infected BALB/c mice

    Nanomedicine: Nanotechnology, Biology, and Medicine, Vol. 11, Núm. 8, pp. 2003-2012

  2. Clinical testing of a dendritic cell targeted therapeutic vaccine in patients with chronic hepatitis C virus infection

    Molecular Therapy - Methods and Clinical Development, Vol. 2, pp. 15006

2014

  1. Characterization of the CD40L/Oncostatin M/Oncostatin M receptor axis as an antiviral and immunostimulatory system disrupted in chronic HCV infection

    Journal of Hepatology, Vol. 60, Núm. 3, pp. 482-489

  2. Dysregulation of interferon regulatory factors impairs the expression of immunostimulatory molecules in hepatitis C virus genotype 1-infected hepatocytes

    Gut, Vol. 63, Núm. 4, pp. 665-673

2013

  1. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C

    Journal of Hepatology, Vol. 59, Núm. 1, pp. 81-88

  2. Usage of Adenovirus Expressing Thymidine Kinase Mediated Hepatocellular Damage for Enabling Mouse Liver Repopulation with Allogenic or Xenogenic Hepatocytes

    PLoS ONE, Vol. 8, Núm. 9

  3. Validation of an antiviral assay method for quantifying IFN-α5 activity in macaque and human serum

    Bioanalysis, Vol. 5, Núm. 3, pp. 289-305

2012

  1. CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy

    Journal of Immunology, Vol. 189, Núm. 7, pp. 3299-3310

  2. Modulation of regulatory T-cell activity in combination with interleukin-12 increases hepatic tolerogenicity in woodchucks with chronic hepatitis B

    Hepatology, Vol. 56, Núm. 2, pp. 474-483

2011

  1. Cardiotrophin-1 promotes a high survival rate in rabbits with lethal fulminant hepatitis of viral origin

    Journal of Virology, Vol. 85, Núm. 24, pp. 13124-13132

  2. Hepatitis C virus induces the expression of CCL17 and CCL22 chemokines that attract regulatory T cells to the site of infection

    Journal of Hepatology, Vol. 54, Núm. 3, pp. 422-431

  3. Improved dendritic cell-based immunization against hepatitis C virus using peptide inhibitors of interleukin 10

    Hepatology, Vol. 53, Núm. 1, pp. 23-31